Business Wire

Incode First to Achieve iBeta’s Highest Level of Independent Identity Security Testing on Both iOS and Android With 0% Error Rate

2.3.2026 15:00:00 CET | Business Wire | Press Release

Share

Incode Technologies, Inc., the global leader in identity security and fraud prevention, today announced that iBeta PAD testing confirmed Incode’s face liveness technology achieves Level 3 Presentation Attack Detection (PAD) conformance under ISO/IEC 30107-3.

"We are the first company to independently achieve iBeta Level 3 conformance on both iOS and Android – with zero errors and without adding friction to users," said Ricardo Amper, Founder & CEO at Incode. "That combination matters. It proves we can meet the highest bar for liveness assurance while keeping onboarding fast and easy, even in regulated and high-risk environments."

Face liveness technology is used in digital onboarding and authentication to confirm a real, live person is present during a selfie capture – not a printed photo, video replay, mask, or other spoofing attempt. It enables organizations to defend remote identity verification flows against account takeovers, synthetic identity fraud, and impersonation scams.

Incode’s solution is passive and completes verification with a single selfie, reducing friction compared to challenge-based experiences while maintaining strong resistance to sophisticated presentation attacks.

This level of assurance matters most at scale – where identity decisions impact conversions, fraud losses, and customer trust across millions of users. Incode operates at that scale, powering trusted experiences for 8 of the top 10 U.S. banks, 8 of the top 9 telecom companies, the top 3 global neobanks, and 4 of the top 5 marketplaces worldwide. To date, Incode has processed more than 7.1 billion trust checks.

From Level 1 to Level 3. A clear progression

In 2019, Incode launched a passive liveness model designed to detect common 2D presentation attacks including printed photos and replay attacks. That release led to Incode becoming the first vendor to pass iBeta Level 1 using a passive liveness approach.

By 2022, Incode expanded its defenses to address advanced 3D mask attacks while continuing to strengthen 2D detection. These improvements enabled Incode to pass iBeta PAD Level 2 testing in early 2023.

In 2026, Incode achieved iBeta PAD Level 3 conformance on both iOS and Android, with a perfect score.

Independent validation at the highest PAD level

"iBeta Level 3 is designed to simulate well-resourced attackers using hyper-realistic masks and specialized fabrication techniques intended to challenge modern biometric systems," said Evan Call, Business Development Manager and Director of Biometrics Sales and Marketing at iBeta Quality Assurance. "Incode’s results demonstrate conformance at Level 3 on both iOS and Android, with 0% APCER and 0% BPCER reported during testing."

APCER (Attack Presentation Classification Error Rate) captures whether spoofing attempts are incorrectly accepted, while BPCER (Bona Fide Presentation Classification Error Rate) captures whether legitimate users are incorrectly rejected. Incode reported 0% on both metrics – no presentation attacks were accepted, and no legitimate users were rejected during the evaluation.

Incode’s verification is completed from a single selfie capture, with no challenge prompts (such as turning head, or smiling), helping reduce friction while maintaining strong resistance to sophisticated presentation attacks.

Why this matters now

Digital onboarding has become the primary gateway to financial services, marketplaces, and government platforms - making identity assurance a critical control point for both security and growth.

Organizations face mounting pressure to reduce fraud losses while minimizing false rejections that disrupt user experience and impact revenue. But as attackers become more sophisticated, it’s increasingly difficult for teams to evaluate liveness vendors under the most demanding real-world conditions, especially across devices, environments, and advanced presentation attacks. Independent testing at the highest available PAD level helps buyers cut through claims and identify the solutions that hold up when stakes are highest.

This milestone reflects Incode’s continued commitment to proprietary innovation and world-class engineering talent globally.

About Incode

Incode is the global leader in trust and identity. Incode’s state-of-the-art AI platform offers a highly secure and seamless AI-based experience that eliminates fraud and drives growth for businesses. With its mission to power a world of trust, Incode works with many of the world’s largest banks, fintechs, telcos, governments, and marketplaces. Incode is headquartered in San Francisco and has offices in Europe and Latin America.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260302578536/en/

Contacts

Seki Berg, incode@sourcecodecomms.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye